As healthcare professionals, we continually strive to improve patient outcomes in all areas, including those suffering from Irritable Bowel Syndrome (IBS). With evolving research, novel approaches in management have emerged, enhancing our ability to provide optimal care for IBS patients.
IBS is a functional gastrointestinal disorder characterized by chronic abdominal pain and altered bowel habits. It's a multifactorial condition involving gut-brain axis dysregulation, altered gut motility, low-grade inflammation, and visceral hypersensitivity.
The Rome IV criteria is currently the gold standard for IBS diagnosis, focusing on the patient's clinical symptoms. It emphasizes the presence of recurrent abdominal pain, on average, at least one day per week in the last three months, associated with two or more of the following: related to defecation, change in frequency of stool, and change in form (appearance) of stool.
Management of IBS is primarily symptom-based and individualized. Recent advances include the use of gut-directed hypnotherapy, cognitive-behavioral therapy, and certain dietary interventions like the low FODMAP diet. Pharmacological advancements include the use of novel agents like eluxadoline and rifaximin for IBS-D and linaclotide for IBS-C.
Best practices involve a patient-centered approach, emphasizing shared decision-making. Regular follow-ups, reassurance, dietary modifications, lifestyle changes, and targeted therapies form the cornerstone of IBS care. The use of probiotics is also widely recognized, although the choice should be individualized.
IBS management has come a long way, with a better understanding of its pathophysiology and the advent of novel therapeutic strategies. As healthcare professionals, it is imperative that we stay updated with these advances to provide the best care possible for our patients.
1.
Toward rapid and comprehensive genetic diagnosis of pediatric cancer through adaptive sequencing
2.
Q&A: Why adolescents and young adults with cancer are falling behind
3.
Fixed-Duration Combo Shows Promise for Relapsed MCL
4.
Hospital receives 300 backpacks designed to help kids get leukemia treatment on the go
5.
A study has developed molecular markers that predict meningioma recurrence.
1.
Ultimate Guide to Oncology Services in the USA
2.
Exploring the Benefits of Teclistamab for Treating Advanced Cancer
3.
Glofitamab: A Breakthrough Therapy for Relapsed/Refractory Mantle Cell Lymphoma
4.
The Importance of Iron Rich Foods in Preventing and Treating Anemia
5.
Unexplained Weight Loss: Revealing Occult Cancers and Paraneoplastic Syndromes
1.
International Cancer Conference
2.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
3.
International Cancer Conference
4.
Asian Symposium on Advancement in Hematology and Oncology (ASAHO)
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Updates on the First Line Management of ALK+ NSCLC
2.
Dacomitinib Case Presentation: Baseline Treatment and Current Status
3.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Continuation
4.
Optimizing Treatment Options in Advanced Urothelial Carcinoma
5.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part II
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation